NCT05814406CompletedPhase 3
To Evaluate the Efficacy and Safety of JW0201 Added on in Patients With T2DM
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase Ⅲ Study to Evaluate the Efficacy and Safety of JW0201 Added on in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With C2202 and C2204
Source: ClinicalTrials.gov · Last updated 9 Sept 2025
Brief summary (registry, in English)
A multicenter, randomized, double blind, placebo controlled, parallel, phase Ⅲ study to evaluate the efficacy and safety of JW0201 added on in patients with type 2 diabetes mellitus who have inadequate glycemic control with C2202 and C2204
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 196 (actual)
- First submitted
- 3 Apr 2023
- Start date
- 12 Jan 2023
- Primary completion date
- 21 Mar 2024
- Lead sponsor
- JW Pharmaceutical
- Diseases
- Type 2 diabetes
- NCT number
- NCT05814406
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 196
- From 12 Jan 2023 to the primary completion date, 21 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Type 1 Diabetes Mellitus
Lab values
- The subject not meet the specified HbA1c and FPG
Who the study is looking for
- Type 2 Diabetes Mellitus
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chosun University Hospital Coordinator of this site? Confirm its status | Gwangju | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.